PriceTargets.com logo

NASDAQ:MRUS - Merus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.43
  • Forecasted Upside: 196.34 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$13.98 As of 05/26/2022 05:00 PM ET
▼ -0.83 (-5.60%)

This chart shows the closing price for MRUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRUS

Analyst Price Target is $41.43
▲ +196.34% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $41.43, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 196.34% upside from the last price of $13.98.

This chart shows the closing price for MRUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Merus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/19/2022CitigroupLower Price TargetBuy$38.00 ➝ $37.00Low
5/10/2022HC WainwrightReiterated RatingBuyMedium
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$45.00Low
2/10/2022Needham & Company LLCInitiated CoverageBuy$45.00Low
11/12/2021HC WainwrightBoost Price TargetBuy$30.00 ➝ $45.00Medium
11/3/2021Royal Bank of CanadaBoost Price TargetSector Perform$21.00 ➝ $33.00High
10/11/2021CitigroupBoost Price TargetBuy$31.00 ➝ $38.00Medium
10/8/2021SVB LeerinkBoost Price TargetOutperform$33.00 ➝ $45.00Low
10/7/2021Roth CapitalBoost Price TargetBuy$32.00 ➝ $40.00High
8/9/2021HC WainwrightReiterated RatingBuy$30.00High
6/11/2021William BlairReiterated RatingBuyLow
6/7/2021CitigroupUpgradeNeutral ➝ BuyHigh
5/9/2021SVB LeerinkReiterated RatingBuy$33.00High
4/8/2021William BlairInitiated CoverageOutperformMedium
3/17/2021Royal Bank of CanadaBoost Price TargetSector Perform$15.00 ➝ $21.00Low
3/17/2021HC WainwrightBoost Price TargetBuy$23.00 ➝ $30.00Medium
3/16/2021SVB LeerinkInitiated CoverageOutperform$33.00High
1/19/2021Roth CapitalBoost Price Target$19.00 ➝ $32.00High
8/7/2020HC WainwrightReiterated RatingBuy$23.00High
7/14/2020HC WainwrightReiterated RatingBuy$23.00High
6/26/2020HC WainwrightInitiated CoverageBuy$23.00High
5/27/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$21.00 ➝ $16.00High
5/18/2020GuggenheimLower Price TargetBuy$26.00 ➝ $23.00High
5/13/2020Royal Bank of CanadaReiterated RatingBuy$21.00Low
11/20/2019GuggenheimInitiated CoverageBuy$25.00Medium
6/28/2019Roth CapitalInitiated CoverageBuy ➝ Buy$20.00High
4/12/2019GuggenheimInitiated CoverageBuy$25.00High
4/5/2019WedbushLower Price TargetOutperform ➝ Outperform$34.00 ➝ $25.00Low
4/3/2019Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$18.00 ➝ $23.00High
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$35.00High
3/21/2019CitigroupLower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00Medium
3/15/2019CitigroupLower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00Low
7/27/2018WedbushReiterated RatingOutperform ➝ Outperform$26.00 ➝ $34.00Low
4/30/2018WedbushReiterated RatingOutperform$26.00 ➝ $32.00Low
1/12/2018WedbushReiterated RatingOutperform$32.00Medium
1/2/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$28.00High
10/26/2017Jefferies Financial GroupReiterated RatingBuy$30.00N/A
10/18/2017Royal Bank of CanadaReiterated RatingBuy$28.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$28.00High
7/14/2017Jefferies Financial GroupReiterated RatingBuy$31.00Low
6/6/2017WedbushReiterated RatingOutperform$32.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 7 very negative mentions
Mentions as of
10/28/2021
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/27/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
12/27/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
1/26/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
3/27/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Mentions as of
4/26/2022
  • 5 very positive mentions
  • 19 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
5/26/2022

Current Sentiment

  • 5 very positive mentions
  • 19 positive mentions
  • 6 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Merus logo
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $13.98
Low: $13.47
High: $14.86

50 Day Range

MA: $22.51
Low: $14.81
High: $29.25

52 Week Range

Now: $13.98
Low: $13.47
High: $33.09

Volume

727,310 shs

Average Volume

199,551 shs

Market Capitalization

$608.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Merus?

The following Wall Street analysts have issued research reports on Merus in the last twelve months: BMO Capital Markets, Citigroup Inc., HC Wainwright, Needham & Company LLC, Roth Capital, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for MRUS.

What is the current price target for Merus?

0 Wall Street analysts have set twelve-month price targets for Merus in the last year. Their average twelve-month price target is $41.43, suggesting a possible upside of 196.3%.
View the latest price targets for MRUS.

What is the current consensus analyst rating for Merus?

Merus currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRUS will outperform the market and that investors should add to their positions of Merus.
View the latest ratings for MRUS.

How do I contact Merus' investor relations team?

Merus' physical mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company's listed phone number is (130) 253-8800 and its investor relations email address is [email protected] The official website for Merus is www.merus.nl. Learn More about contacing Merus investor relations.